Table 1.

Gemcitabine monotherapy versus fluorouracil monotherapy for non-resectable (locally advanced or advanced) pancreatic cancer

Ref	Study design	Population	Intervention and comparison	Outcome
	SR, 2 RCTs	279 people with locally advanced or metastatic cancer	Gemcitabine monotherapy v fluorouracil monotherapy	Mortality at 12 months:Lower with gemcitabine compared with fluorouracil but of borderline significance (2 RCTs; 90/98 [92%] with gemcitabine monotherapy v 105/130 [81%] with fluorouracil monotherapy; RR 1.12, 95% CI 1.00 to 1.25)
	SR, 2 RCTs	197 people	Gemcitabine monotherapy v fluorouracil monotherapy	Overall survival:2 RCTs, 197 people; HR 0.75, 95% CI 0.42 to 1.31; absolute numbers not reported
	SR, 2 RCTs		Gemcitabine monotherapy v fluorouracil monotherapy	Time to progression:Significantly increased with gemcitabine: 2 RCTs, 197 people; HR 0.46, 95% CI 0.31 to 0.70; absolute numbers not reported
				Progression-free survival:2 RCTs, 197 people; HR 0.94, 95% CI 0.58 to 1.53; absolute numbers not reported
				Overall response rate:Significantly increased with gemcitabine: 1 RCT, 126 people; RR 0.14, 95% CI 0.01 to 2.66; absolute numbers not reported
				Grade 3 and 4 neutropenia:1 RCT, 126 people; 25% with gemcitabine v 5% with fluorouracil; absolute numbers not reported

Ref, reference. ; SR, systematic review, HR, hazard ratio.